Potential Role of 68Ga-NOTA-Duramycin PET/CT Imaging for Early Response Evaluation in a Lymphoma Patient: A Case Report. (26th January 2023)

• Record Type: Journal Article
• Authors: Kaur, Gurvinder; Shukla, Jaya; Sood, Ashwani; Prakash, Gaurav; Krishnaraju, Venkata Subramanian; Rana, Nivedita; Pandey, Somit; Singh, Harmandeep; Kumar, Rajender; Bal, Amanjit; Mittal, Bhagwant Rai
• Is Part Of: Clinical nuclear medicine. Volume 48:Number 1(2023)
• Page Start: e19
• Page End: e21
• Publication Date: 2023-01-26
• Subjects: 68Ga-NOTA-duramycin -- duramycin -- PET/CT -- response evaluation -- apoptosis -- lymphoma; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004462
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: Duramycin, a 19 amino acids peptide, is known for its potential to target phosphatidylethanolamine. During cell death (apoptosis), rearrangement of membrane phospholipids results in the externalization of phosphatidylethanolamine to the outer leaflet of the cell membrane, which can be imaged using 68 Ga-NOTA-duramycin. We report 68 Ga-NOTA-duramycin imaging in a 50-year-old man with biopsy-proven diffuse large B-cell lymphoma planned for anthracycline-based chemotherapy. 68 Ga-NOTA-duramycin PET/CT imaging along with 18 F-FDG PET/CT was performed before and after 2 cycles of chemotherapy. The tracer avidity in interim 68 Ga-NOTA-duramycin PET/CT showed its diagnostic potential to assess early response to chemotherapy.